Search
Displaying all 3 results
Alirocumab
go.drugbank.com/drugs/DB09302
ApprovedInvestigational
Alirocumab is a biopharmaceutical that obtained FDA approval in July 2015 as a second line treatment for high cholesterol in adults whose LDL-cholesterol (LDL-C) is not controlled by the combination of diet and statin treatment. It is a human monoclonal antibody part of the family of the PCSK9 inhibitors which are a...
Evolocumab
go.drugbank.com/drugs/DB09303ApprovedInvestigationalEvolocumab is the second PCSK9 inhibitor on the market, first being alirocumab.
Enlicitide
go.drugbank.com/drugs/DB22580ApprovedInvestigational[L63795] Unlike the monoclonal antibody PCSK9 inhibitors ([evolocumab], [alirocumab]), enlicitide is administered orally as a once-daily tablet.